各项收入占比是对year ended 2025-12-31的估算，并非来自已提交报告的数字。
Routine and specialty diagnostic tests
Laboratory tests on patient samples, including tests used to diagnose and monitor diseases, as well as occupational, wellness and forensic deoxyribonucleic acid (DNA) testing.
ColoSense
A stool-based colorectal cancer screening test that people collect at home; it is approved by the U.S. Food and Drug Administration (FDA).
PlasmaDetect genome minimal residual disease (MRD)
A blood test being evaluated for monitoring whether early-stage lung cancer returns after treatment.
Labcorp OnDemand
A service through which consumers can order certain health and wellness tests directly, including tests for cancer screening, allergies and men's and women's health.
Central laboratory services
Laboratory testing for pharmaceutical and biotechnology companies conducting clinical studies of medicines.
Early development laboratory services
Laboratory services supporting early stages of drug research and development.
Labcorp tests patient samples at its laboratories, performing routine and specialty tests for diagnosing and monitoring health conditions. Its Biopharma Laboratory Services business performs laboratory work for pharmaceutical, biotechnology, medical device and diagnostic companies, including central laboratory testing and early development services. Patients can also order some tests directly through Labcorp OnDemand.
基于 Labcorp Holdings Inc. 自己向美国证券交易委员会（SEC）提交的申报文件。数字如实呈报，每股历史已重述到今天的股数口径。 这是对一门生意的描述——不是投资建议，也不是买卖任何证券的推荐。
US$370.57-0.5%11月13日 收盘
数据截至2026年9月30日，来自2026年10月30日提交的10-Q
Labcorp sells medical testing to doctors, hospitals, health plans and patients, plus drug-development laboratory testing to pharmaceutical and biotechnology companies.
Just reported
From Labcorp's results release of 2026年10月28日; its quarterly report has since been filed.
Actual
US$3.81B
+6.9% y/y
+2.1% q/q
Guided
—
No guide given
Actual
US$3.22
+3.2% y/y
-12% q/q
Guided
—
No guide given
Actual
US$402.1M
+1.4% y/y
-11% q/q
Guided
—
No guide given
Full year 2026
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
The themes Labcorp is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Graded A or B and worth $2B or more: A first, then the largest.
TMOThermo Fisher Scientific Inc.US$259.4BA+
IDXXIdexx Laboratories Inc.US$55.5BA+
IQVIQVIA Holdings Inc.US$43.7BA
ILMNIllumina, Inc.US$31.3BA+
DGXQuest Diagnostics IncUS$28.6BARose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
DHRDanaher Corporation2026年10月21日CBGraded C, now B
MCKMckesson Corporation2026年11月4日BAGraded B, now A
CVSCVS Health Corp2026年11月4日BAGraded B, now A
EWEdwards Lifesciences Corporation2026年11月4日BAGraded B, now A
GEHCGE Healthcare Technologies Inc.2026年10月28日CAGraded C, now AGrade A
价格下方的色带显示每个日期的评级，仅依据当时已公开的文件计算。
显示 Labcorp Holdings Inc. 评级历史 41 个季度中的 2 个。 其余 39 个可回溯到 2016年10月。
